Skip to main content
Explore URMC
menu

Lung Cancer: Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

Research Question:
What are the good and bad effects of using nivolumab (OPDIVO®) along with the usual chemotherapy regimen of cisplatin/carboplatin and etoposide compared to using the usual chemotherapy approach alone?

Basic Study Information

Purpose:
If you decide to participate in this study you will be assigned to one of the two treatment groups by chance. This is done by chance because no one knows if one study group is better or worse than the other. Group 1 will receive the study drug nivolumab in combination with the usual chemotherapy regimen of platinum (cisplatin or carboplatin) and etoposide administered by an intravenous (IV) infusion. Group 2 will receive the usual chemotherapy alone administered by an intravenous (IV) infusion.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03382561?term=EA5161&rank=1 https://clinicaltrials.gov/ct2/show/NCT03382561?term=EA5161&rank=1
Study Reference #: CLUN18052

Lead Researcher (Principal Investigator)

Lead Researcher: Megan Baumgart

Study Contact Information

Study Coordinator: Amy Jasek
Phone: (585) 273-1912
Email: Amy_Jasek@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Small Cell Lung Carcinoma

More information about Lung Cancer

Return to Search